<DOC>
	<DOCNO>NCT01301820</DOCNO>
	<brief_summary>Phase II Multicentric Trial Open Label , Multicenter , randomize evaluate efficacy Maintenance Therapy First Complete Remission After Induction Elderly ( ≥ 60 ) Fit Patients With Poor Prognosis Acute Myeloid Leukemia ( AML ) . The disease-free survival ( DFS ) patient include study compare one two previously report group patient treat LIA induction therapy</brief_summary>
	<brief_title>Elderly Patients With Acute Myeloid Leukemia ( AML ) , Maintenance Phase After Complete Remission ( CR )</brief_title>
	<detailed_description>- The primary objective study improve DFS alternate schema combine azacitidine lenalidomide elderly fit patient previously untreated AML high risk cytogenetics secondary AML , achieve either complete remission LIA induction therapy - The secondary objective determine relapse incidence , overall survival , event free survival 1 2 year follow-up , toxicity treatment , incidence infectious event . - To define gene expression promoter methylation signature associate CR absence relapse patient receive azacitidine lenalidomide . Gene promoter methylation gene expression profile perform diagnosis , CR , 2 course azacitidine lenalidomide order give insight within mechanism involve use 2 drug identify new epigenetic prognostic marker .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Cytologically histologically confirm acute myeloid leukemia ( AML ) : At least 60 year age fit intensive chemotherapy : PS &lt; 2 ( ECOG ) Absence significant comorbidities Less 75 years* age LAM high risk feature ( blast &gt; 20 % bone marrow ) Poor risk cytogenetics Life expectancy &gt; 1 month Affiliated social security regimen No granulocytic sarcoma sole site disease Able willing provide write sign inform consent Total bilirubin &gt; 2 time upper limit normal AST ALT and/or alkaline phosphatase &gt; 4 time upper limit normal relation AML . Factor V &lt; 50 % without DIC ( Disseminated Intravascular Coagulation ) NYHA class III IV congestive heart failure ( Echo &lt; 40 % , LVEF &lt; 50 % ) , Unstable angina pectoris , Serious cardiac arrhythmia Renal failure relate AML : serum creatinin &gt; 170 μmol/L clearance creatinin ≤ 50 mL/mn Known HIV 1 HIV 2 positivity Prior therapy azacitidine lenalidomide Psychiatric illness social situation would preclude compliance study requirement Uncontrolled infection Urgent chemotherapy DIC , spontaneous tumoral lyse syndrome , leucostase without cytogentic result Women pregnant breastfeed Women unwilling unable use acceptable contraceptive method avoid pregnancy Men unwilling unable use acceptable method birth control</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>maintenance treatment</keyword>
	<keyword>Disease free survival</keyword>
</DOC>